Allicia C. Girvan

1.2k total citations
31 papers, 826 citations indexed

About

Allicia C. Girvan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Allicia C. Girvan has authored 31 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Allicia C. Girvan's work include Lung Cancer Treatments and Mutations (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Lung Cancer Research Studies (6 papers). Allicia C. Girvan is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Lung Cancer Research Studies (6 papers). Allicia C. Girvan collaborates with scholars based in United States, Germany and Spain. Allicia C. Girvan's co-authors include Shelia D. Thomas, Paula J. Bates, Lavona Casson, William M. Pierce, Yun Teng, Simone Jüliger, Mark W. Ball, Shirish Barve, Jon B. Klein and Mingwei Qian and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Allicia C. Girvan

30 papers receiving 812 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Allicia C. Girvan United States 12 505 239 199 69 50 31 826
S. Pezzulli United States 10 403 0.8× 352 1.5× 94 0.5× 83 1.2× 27 0.5× 19 704
Colby S. Shemesh United States 15 343 0.7× 373 1.6× 145 0.7× 60 0.9× 35 0.7× 33 899
S. Ménard Canada 7 368 0.7× 243 1.0× 285 1.4× 208 3.0× 35 0.7× 10 697
Steve Swenson United States 11 289 0.6× 217 0.9× 107 0.5× 86 1.2× 20 0.4× 19 658
Feifei Na China 14 210 0.4× 166 0.7× 224 1.1× 111 1.6× 48 1.0× 33 618
Songbing Qin China 14 179 0.4× 440 1.8× 206 1.0× 92 1.3× 45 0.9× 54 789
Minsig Choi United States 14 190 0.4× 360 1.5× 134 0.7× 104 1.5× 25 0.5× 28 549
Heungnam Kim United States 10 274 0.5× 152 0.6× 85 0.4× 61 0.9× 107 2.1× 11 574
Corey J. Williams United States 3 228 0.5× 664 2.8× 148 0.7× 77 1.1× 22 0.4× 4 930
Coleman E. Johnson United States 2 224 0.4× 663 2.8× 147 0.7× 74 1.1× 22 0.4× 3 925

Countries citing papers authored by Allicia C. Girvan

Since Specialization
Citations

This map shows the geographic impact of Allicia C. Girvan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allicia C. Girvan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allicia C. Girvan more than expected).

Fields of papers citing papers by Allicia C. Girvan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allicia C. Girvan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allicia C. Girvan. The network helps show where Allicia C. Girvan may publish in the future.

Co-authorship network of co-authors of Allicia C. Girvan

This figure shows the co-authorship network connecting the top 25 collaborators of Allicia C. Girvan. A scholar is included among the top collaborators of Allicia C. Girvan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allicia C. Girvan. Allicia C. Girvan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Parikh, Neehar D., Allicia C. Girvan, Jiat Ling Poon, et al.. (2023). Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study. BMC Cancer. 23(1). 66–66. 2 indexed citations
2.
Leith, Andrea, Urpo Kiiskinen, Allicia C. Girvan, et al.. (2022). Physician- and Patient-Reported Symptom Concordance and Association with Quality of Life in Hepatocellular Carcinoma. Future Oncology. 18(33). 3727–3740. 2 indexed citations
3.
Valle, Juan W., Li‐Yuan Bai, Р. В. Орлова, et al.. (2020). Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.. Journal of Clinical Oncology. 38(4_suppl). 477–477. 23 indexed citations
4.
5.
Zhu, Andrew X., Ryan David Nipp, Richard S. Finn, et al.. (2020). Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open. 5(4). e000797–e000797. 21 indexed citations
6.
Santini, Valeria, David Valcárcel, Uwe Platzbecker, et al.. (2019). Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clinical Cancer Research. 25(23). 6976–6985. 60 indexed citations
7.
8.
Gable, Julia, David W. Ayer, Allicia C. Girvan, et al.. (2018). PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN. Value in Health. 21. S76–S76. 1 indexed citations
9.
Cui, Zhanglin Lin, et al.. (2018). Treatment patterns and costs of care for patients diagnosed with hepatocellular carcinoma (HCC) in the United States (U.S.). Annals of Oncology. 29. v27–v27. 5 indexed citations
10.
11.
Happich, Michael, Alan Brnabic, D Faries, et al.. (2016). Reweighting Rct Evidence To Better Reflect Real Life: A Case Study of The Innovation Medicines Initiative. Value in Health. 19(7). A711–A711. 2 indexed citations
12.
Moro‐Sibilot, Denis, Egbert F. Smit, Javier de Castro, et al.. (2015). Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer. 88(2). 215–222. 55 indexed citations
13.
Moro‐Sibilot, Denis, Egbert F. Smit, Javier de Castro, et al.. (2015). Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer. 90(3). 427–432. 54 indexed citations
14.
Smit, Egbert F., Denis Moro‐Sibilot, Javier de Castro, et al.. (2015). Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. Lung Cancer. 92. 35–40. 13 indexed citations
15.
Girvan, Allicia C., Yiu-Keung Lau, Lee Bowman, et al.. (2013). Treatment patterns among cancer patients with anemia who do not respond to erythropoietin-stimulating agents.. Journal of Clinical Oncology. 31(15_suppl). e20525–e20525. 1 indexed citations
16.
Pennella, Eduardo J., Coleman K. Obasaju, Gerhardt Pohl, et al.. (2013). Prospective Observational Comparison of Clinical Outcomes Between African-American and Caucasian Patients Receiving Second-Line Treatment With Pemetrexed for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 14(6). 726–735. 5 indexed citations
17.
Schnabel, Philipp A., Egbert F. Smit, Javier de Castro, et al.. (2012). Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME). Lung Cancer. 78(3). 263–269. 16 indexed citations
18.
19.
Girvan, Allicia C., Yun Teng, Lavona Casson, et al.. (2006). AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin. Molecular Cancer Therapeutics. 5(7). 1790–1799. 202 indexed citations
20.
Xu, Xiaohua, Shelia D. Thomas, Allicia C. Girvan, et al.. (2001). Inhibition of DNA Replication and Induction of S Phase Cell Cycle Arrest by G-rich Oligonucleotides. Journal of Biological Chemistry. 276(46). 43221–43230. 136 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Pezzulli Breakdown of academic impact, for papers by Colby S. Shemesh Breakdown of academic impact, for papers by S. Ménard Breakdown of academic impact, for papers by Steve Swenson Breakdown of academic impact, for papers by Feifei Na Breakdown of academic impact, for papers by Songbing Qin Breakdown of academic impact, for papers by Minsig Choi Breakdown of academic impact, for papers by Heungnam Kim Breakdown of academic impact, for papers by Corey J. Williams Breakdown of academic impact, for papers by Coleman E. Johnson
Rankless by CCL
2026